Report on discontinuation of tyrosine kinase inhibitor therapy and the cure of chronic myelogenous leukemia in the 54th ASH annual meeting
10.3760/cma.j.issn.1009-9921.2013.01.006
- VernacularTitle:慢性粒细胞白血病治疗中关于停药及治愈问题的研究进展:第54届美国血液学会年会报道
- Author:
Lihua ZHANG
;
Jianda HU
- Publication Type:Journal Article
- Keywords:
Leukemia,myelogenous,chronic;
Tyrosine kinase inhibitor;
Discontinuation;
Cure;
Molecular relapse;
ASH annul meeting
- From:
Journal of Leukemia & Lymphoma
2013;22(1):13-16
- CountryChina
- Language:Chinese
-
Abstract:
With the great success of imatinib mesylate(IM) and other tyrosine kinase inhibitor (TKI),chronic myelogenous leukemia (CML) is taken as a successful model of targeted therapies for human cancer.Although the emergence of TKI has greatly improved the prognosis of CML,the long-term TKI treatment may bring the problems of drug resistance,serious side effects,poor compliance,and heavy economic burden.Recently,people focus on whether patients would be cured after discontinuation of TKI treatment.Here,the progresses on discontinuation of TKI therapy in CML presented in the 54th American Society of Hematology (ASH) annual meeting were reviewed.
